MEGGLE returns to DDL 2017 with enhanced inhalation offers
Press Release | MEGGLE Excipients & Technology
NOVEMBER 29, 2017
Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE Excipients & Technology (MEGGLE) is returning as an exhibitor to the Drug Delivery to the Lungs (DDL) Conference in Edinburgh, showcasing its expanded range of lactose anhydrous and lactose monohydrate-based inhalation agents and excipients.
For the fifth year in succession, MEGGLE will be a DDL exhibitor with a stand at Booth 234 at the Edinburgh International Conference Center (EICC) featuring a display showcasing latest developments.
Micronized inhalation lactose
The stand will feature the enhanced properties of MEGGLE products, including its newly developed micronized lactose grade InhaLac 500, specifically designed for inhalation.
Developed at MEGGLE’s Wasserburg laboratories in Germany, InhaLac 500 features very small milled particles, high cohesive properties and even distribution, with 90% of the particles being smaller than 10 μm (x50 ≤ 5 μm). This allows a wider choice of applications as fines or as co-agglomerate in dry powder inhalation products. A further key benefit is long shelf life, with high stability reducing retest intervals to 12 months, twice as long as competitor products.
“We have a long and proud relationship with DDL, having attended since more than 10 years and contributing many posters and sponsorships,” said Eugen Schwarz, MEGGLE Head of Research & Development.
Once again, MEGGLE will provide significant input to the conference agenda, with a poster on “Influence of the storage conditions on tenary powder mixtures” based on research by M. Hertel and others in MEGGLE’s Wasserburg laboratories.
The MEGGLE presence in Edinburgh will be complemented by Sabine Hauptsteinand Diana Kesetovic, Project Manager for Dry Powder Inhalers.
About MEGGLE Wasserburg
Bavarian-based MEGGLE Wasserburg is one of the world’s experts in lactose based excipients and powder technology.
From its roots as a dairy operation in the late 1880s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.
MEGGLE Excipients & Technology has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.
A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for solid dosage form applications, where they can deliver maximum performance.
The company has introduced several pioneering products, notably Tablettose®, the world’s first agglomerated lactose for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first direct compression co-processed excipient using a hypromellose-lactose base for modified sustained release and controlled release formulations.
About DDL 2017
The Drug Delivery to the Lungs Conference (DDL) provides an annual forum for scientists, academics, clinicians, regulatory and industry specialists involved in developing medicines for inhalation.
DDL2017 is a three-day event opening December 6 at the EICC at The Exchange in the Scottish capital of Edinburgh.
The 2017 conference will feature five themed sessions each with a combination of invited and submitted lectures given by experts in the field of inhalation and students working to advance respiratory science.
The conference will be preceded by the SimInhale Pre-symposium on designing Inhalers for children and Infants, during the morning of Wednesday, December 6.
The event is organized by The Aerosol Society, with more information at: https://aerosol-soc.com/events/ddl2017.
Margit Bonnetsmüller, Project Manager Marketing, MEGGLE Excipients & Technology Business Group
Tel: +49 8071 73 476